Table 2.
Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Positive LR | Negative LR | AUC (95% CI) | |
---|---|---|---|---|---|---|---|
Training Cohort | |||||||
AFP‐negative HCC and early‐stage HCC | |||||||
HCC vs. HC + BLT + CHB + LC | 71.2 | 92.6 | 68.4 | 93.4 | 9.59 | 0.31 | 0.891 (0.856‐0.920) |
HCC vs. CHB + LC | 65.8 | 85.7 | 82.8 | 68.4 | 4.6 | 0.40 | 0.819 (0.744‐0.880) |
Early‐stage HCC vs. HC + BLT + CHB + LC | 63.4 | 90.7 | 46.4 | 95.1 | 6.83 | 0.40 | 0.839 (0.797‐0.875) |
Early‐stage HCC vs. CHB + LC | 61.0 | 81.0 | 67.6 | 76.1 | 3.20 | 0.48 | 0.754 (0.660‐0.833) |
AFP‐positive HCC and early‐stage HCC | |||||||
HCC vs. HC + BLT + CHB + LC | 76.5 | 95.7 | 88.1 | 90.6 | 17.64 | 0.25 | 0.899 (0.868‐0.925) |
HCC vs. CHB + LC | 76.5 | 85.7 | 92.0 | 62.8 | 5.35 | 0.27 | 0.842 (0.784‐0.890) |
Early‐stage HCC vs. HC + BLT + CHB + LC | 65.8 | 95.7 | 64.1 | 96.0 | 15.18 | 0.36 | 0.822 (0.778‐0.860) |
Early‐stage HCC vs. CHB + LC | 65.8 | 85.7 | 73.5 | 80.6 | 4.61 | 0.40 | 0.748 (0.652‐0.829) |
Validation Cohort | |||||||
AFP‐negative HCC and early‐stage HCC | |||||||
HCC vs. HC + BLT + CHB + LC | 68.2 | 91.0 | 60.8 | 93.3 | 7.57 | 0.35 | 0.805 (0.762‐0.843) |
HCC vs. CHB + LC | 50.0 | 85.9 | 78.6 | 62.5 | 3.56 | 0.58 | 0.725 (0.640‐0.800) |
Early‐stage HCC vs. HC + BLT + CHB + LC | 68.0 | 91.0 | 37.0 | 97.3 | 7.55 | 0.35 | 0.788 (0.741‐0.830) |
Early‐stage HCC vs. CHB + LC | 64.0 | 85.9 | 64.0 | 85.9 | 4.55 | 0.42 | 0.742 (0.639‐0.829) |
AFP‐positive HCC and early‐stage HCC | |||||||
HCC vs. HC + BLT + CHB + LC | 73.9 | 90.7 | 77.3 | 89.0 | 7.93 | 0.29 | 0.858 (0.823‐0.888) |
HCC vs. CHB + LC | 66.7 | 85.9 | 91.1 | 54.5 | 4.74 | 0.39 | 0.808 (0.747‐0.860) |
Early‐stage HCC vs. HC + BLT + CHB + LC | 78.0 | 91.3 | 58.2 | 96.4 | 8.97 | 0.24 | 0.883 (0.846‐0.914) |
Early‐stage HCC vs. CHB + LC | 62.0 | 84.4 | 75.6 | 74.0 | 3.97 | 0.45 | 0.766 (0.677‐0.840) |
Abbreviations: CI, confidence interval; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.